Form 4: Rhythm Pharmaceuticals Chief HR Officer Exercises Options and Sells Shares Under Pre-Arranged Plan

Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, Inc., executed a planned sale of 7,031 common shares after exercising stock options on June 6, 2025.

Summary

• Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, Inc. (RYTM), engaged in an insider transaction on June 6, 2025.
• She exercised 7,031 stock options at an exercise price of $6.8 per share.
• Concurrently, she sold 7,031 shares of common stock at a weighted average price of $68.0465 per share.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan adopted on December 16, 2024.
• Following these transactions, Ms. Cramer beneficially owns 19,209 shares of common stock and 28,128 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, this transaction was pre-planned under a Rule 10b5-1 plan, which mitigates concerns about opportunistic trading. It represents a routine liquidity event for an executive.

Positives

• The exercise of stock options indicates that the options were significantly in-the-money, as the exercise price ($6.8) is substantially lower than the sale price ($68.0465).
• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned liquidity event for personal financial management rather than a reaction to new, undisclosed information.

Negatives

• The sale of shares by a Chief Human Resources Officer, even if planned, could be perceived by some investors as a lack of strong conviction in the company's future stock price, although it is a common practice for diversification or liquidity.

Risks

• Potential for negative investor sentiment if the market misinterprets the insider sale as a lack of confidence, despite it being a planned transaction under a Rule 10b5-1 plan.

Future Outlook

NA

Management Comments

• "The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024."
• "The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: May observe the insider sale, which could lead to varied interpretations regarding management's confidence, though the 10b5-1 plan context should alleviate significant concern.

Key Dates

Keywords

Rhythm Pharmaceuticals, RYTM, insider trading, Form 4, stock options, common stock, Pamela J. Cramer, Chief Human Resources Officer, Rule 10b5-1 plan, equity compensation